HUE043842T2 - RNAi-indukált huntingtin gén szuppresszió - Google Patents
RNAi-indukált huntingtin gén szuppresszióInfo
- Publication number
- HUE043842T2 HUE043842T2 HUE15817385A HUE15817385A HUE043842T2 HU E043842 T2 HUE043842 T2 HU E043842T2 HU E15817385 A HUE15817385 A HU E15817385A HU E15817385 A HUE15817385 A HU E15817385A HU E043842 T2 HUE043842 T2 HU E043842T2
- Authority
- HU
- Hungary
- Prior art keywords
- gene suppression
- huntingtin gene
- rnai induced
- induced huntingtin
- rnai
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14200308 | 2014-12-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUE043842T4 HUE043842T4 (hu) | 2019-08-28 |
HUE043842T2 true HUE043842T2 (hu) | 2019-09-30 |
Family
ID=52282540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15817385A HUE043842T2 (hu) | 2014-12-24 | 2015-12-23 | RNAi-indukált huntingtin gén szuppresszió |
Country Status (25)
Country | Link |
---|---|
US (4) | US10174321B2 (hu) |
EP (2) | EP3237618B1 (hu) |
JP (2) | JP6839094B2 (hu) |
KR (1) | KR102636633B1 (hu) |
CN (1) | CN108064292B (hu) |
AU (1) | AU2015370903B2 (hu) |
CA (1) | CA2971920C (hu) |
CO (1) | CO2017007335A2 (hu) |
CY (1) | CY1121733T1 (hu) |
DK (1) | DK3237618T3 (hu) |
EA (1) | EA037696B1 (hu) |
ES (1) | ES2732023T3 (hu) |
HK (1) | HK1246344B (hu) |
HR (1) | HRP20190992T1 (hu) |
HU (1) | HUE043842T2 (hu) |
IL (1) | IL252990B (hu) |
LT (1) | LT3237618T (hu) |
MX (1) | MX2017008500A (hu) |
PL (1) | PL3237618T3 (hu) |
PT (1) | PT3237618T (hu) |
RS (1) | RS58862B1 (hu) |
SI (1) | SI3237618T1 (hu) |
SM (1) | SMT201900347T1 (hu) |
TR (1) | TR201908969T4 (hu) |
WO (1) | WO2016102664A1 (hu) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
SG10201403841QA (en) | 2009-07-06 | 2014-09-26 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
CN112007045A (zh) | 2012-07-13 | 2020-12-01 | 波涛生命科学有限公司 | 手性控制 |
BR112015000784A8 (pt) | 2012-07-13 | 2018-04-03 | Wave Life Sciences Japan | Grupo auxiliar assimétrico |
MX356830B (es) | 2012-07-13 | 2018-06-15 | Shin Nippon Biomedical Laboratories Ltd | Adyuvante de acido nucleico quiral. |
EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
CN106068325B (zh) | 2014-01-16 | 2021-07-09 | 波涛生命科学有限公司 | 手性设计 |
CN112410339A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
JP2017535266A (ja) | 2014-11-14 | 2017-11-30 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)を治療する組成物および方法 |
HUE043842T2 (hu) * | 2014-12-24 | 2019-09-30 | Uniqure Ip Bv | RNAi-indukált huntingtin gén szuppresszió |
NZ772770A (en) | 2015-02-10 | 2024-10-25 | Genzyme Corp | Variant rnai |
WO2016161388A1 (en) | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
AU2016366694C1 (en) | 2015-12-10 | 2021-03-25 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
EP3458589A4 (en) | 2016-05-18 | 2020-01-01 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
RU2758488C2 (ru) | 2016-05-18 | 2021-10-28 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
US10457940B2 (en) * | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
WO2018204803A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
JP7376471B2 (ja) | 2017-06-05 | 2023-11-08 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するための化合物 |
JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | 2テイル自己デリバリー型siRNAおよび関連方法 |
MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
CN111356763B (zh) * | 2017-09-22 | 2024-03-12 | 建新公司 | 变体RNAi |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
CN108384803A (zh) * | 2017-12-19 | 2018-08-10 | 上海百力格生物技术有限公司 | 一种用于miRNA干扰载体构建筛选特异对照的质粒及其构建方法 |
CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
EP3793566A4 (en) * | 2018-05-15 | 2022-03-16 | University of Washington | Compositions and methods for reducing spliceopathy and treating rna dominance disorders |
EP3794125A4 (en) * | 2018-05-15 | 2022-07-13 | University of Massachusetts | MODIFIED AAV CONSTRUCTS AND USES THEREOF |
WO2020005873A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
EA202092899A1 (ru) | 2018-06-27 | 2021-05-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Гетероарильные соединения для лечения болезни гентингтона |
EP3818161A1 (en) | 2018-07-02 | 2021-05-12 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
EP3850098A1 (en) | 2018-09-12 | 2021-07-21 | uniQure IP B.V. | Rnai induced c9orf72 suppression for the treatment of als/ftd |
WO2020104469A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | Method and means to deliver mirna to target cells |
AU2019385598A1 (en) | 2018-11-19 | 2021-06-03 | Uniqure Ip B.V. | RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3 |
EP3884067A1 (en) | 2018-11-19 | 2021-09-29 | uniQure IP B.V. | A companion diagnostic to monitor the effects of gene therapy |
BR112021013109A2 (pt) * | 2019-01-09 | 2021-10-13 | Universidade De Coimbra | Rna de fita dupla e seus usos. |
US11492619B2 (en) | 2019-01-18 | 2022-11-08 | University Of Massachusetts | Dynamic pharmacokinetic-modifying anchors |
US20220251567A1 (en) | 2019-07-10 | 2022-08-11 | Inserm (Institut National De La Santè Et De La Recherche Médicale) | Methods for the treatment of epilepsy |
AU2020329155A1 (en) | 2019-08-09 | 2022-03-10 | University Of Massachusetts | Chemically modified oligonucleotides targeting SNPs |
WO2021053018A1 (en) | 2019-09-16 | 2021-03-25 | Uniqure Ip B.V. | Targeting misspliced transcripts in genetic disorders |
KR20220094213A (ko) * | 2019-11-01 | 2022-07-05 | 알닐람 파마슈티칼스 인코포레이티드 | 헌팅틴 (HTT) iRNA 제제 조성물 및 이의 사용 방법 |
EP4051280A1 (en) | 2019-11-01 | 2022-09-07 | Novartis AG | The use of a splicing modulator for a treatment slowing progression of huntington's disease |
JP2023521347A (ja) * | 2020-04-07 | 2023-05-24 | ユニキュアー アイピー ビー.ブイ. | アンジオポエチン様3(angptl3)をサイレンシングするための遺伝子構築物及びその使用 |
WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
US20220090069A1 (en) * | 2020-08-03 | 2022-03-24 | University Of Massachusetts | Oligonucleotides for htt-1a modulation |
CN117203336A (zh) | 2021-03-29 | 2023-12-08 | 阿尔尼拉姆医药品有限公司 | 亨廷顿蛋白(HTT)iRNA药剂组合物以及其使用方法 |
TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
EP4317434A1 (en) * | 2021-03-30 | 2024-02-07 | Nanjing University | Rna delivery system for treatment of huntington's disease |
WO2022268835A1 (en) | 2021-06-21 | 2022-12-29 | Uniqure Biopharma B.V. | Gene constructs for silencing alpha-synuclein and uses thereof |
JP2025503910A (ja) * | 2022-01-27 | 2025-02-06 | アスクレピオス バイオファーマシューティカル, インコーポレイテッド | 神経疾患を処置するための組成物 |
EP4508214A1 (en) | 2022-04-12 | 2025-02-19 | uniQure biopharma B.V. | Nucleic acid regulation of c9orf72 |
CN119032174A (zh) | 2022-04-12 | 2024-11-26 | 优尼科生物制药有限公司 | ApoE的核酸调节 |
WO2023198662A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Novel systems for nucleic acid regulation |
EP4508216A1 (en) | 2022-04-12 | 2025-02-19 | uniQure biopharma B.V. | Nucleic acid regulation of snca |
WO2024218204A1 (en) | 2023-04-18 | 2024-10-24 | Uniqure Biopharma B.V. | Gene delivery vehicles comprising rna and antibodies |
WO2025051805A1 (en) | 2023-09-04 | 2025-03-13 | Uniqure Biopharma B.V. | Novel neurotropic recombinant adeno-associated virus particles |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004101787A1 (ja) | 2003-05-14 | 2004-11-25 | Japan Science And Technology Agency | ハンチンチン遺伝子の発現抑制 |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
EP1735443A2 (en) | 2004-04-14 | 2006-12-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
PL1945779T3 (pl) | 2005-10-20 | 2013-08-30 | Uniqure Ip Bv | Ulepszone wektory AAV produkowane w komórkach owadzich |
WO2007148971A2 (en) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
CA2662704A1 (en) | 2006-07-07 | 2008-01-10 | University Of Massachusetts | Rna silencing compositions and methods for the treatment of huntington's disease |
WO2008134646A2 (en) * | 2007-04-26 | 2008-11-06 | University Of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
US8258286B2 (en) * | 2007-04-26 | 2012-09-04 | University Of Iowa Research Foundation | Reduction of off-target RNA interference toxicity |
CN101868547B (zh) | 2007-07-26 | 2016-03-16 | 尤尼克尔Ip股份有限公司 | 包含具有差别密码子偏性的重复编码序列的杆状病毒载体 |
AU2009215987B2 (en) | 2008-02-19 | 2015-01-22 | Uniqure Ip B.V. | Optimisation of expression of parvoviral rep and cap proteins in insect cells |
CN102439136A (zh) * | 2009-03-26 | 2012-05-02 | 加州大学校董 | 产生用于疾病修饰的抑制性rna的间充质干细胞 |
CN107083400A (zh) * | 2009-05-02 | 2017-08-22 | 建新公司 | 神经退行性疾病的基因治疗 |
WO2011122950A1 (en) | 2010-04-01 | 2011-10-06 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Monomeric duplex aav vectors |
PT2561078T (pt) * | 2010-04-23 | 2018-12-03 | Cold Spring Harbor Laboratory | Sharn com uma conceção estrutural inovadora |
CN102946908B (zh) * | 2010-06-18 | 2015-04-22 | Lsip基金运营联合公司 | 显性等位基因表达抑制剂 |
KR101961347B1 (ko) | 2011-09-08 | 2019-03-25 | 유니큐어 아이피 비.브이. | Aav 제조물로부터 오염 바이러스의 제거 |
CN103224556B (zh) * | 2013-01-31 | 2015-04-15 | 清华大学 | 亨廷顿舞蹈症的靶位蛋白质及其编码基因和应用 |
HUE043842T2 (hu) * | 2014-12-24 | 2019-09-30 | Uniqure Ip Bv | RNAi-indukált huntingtin gén szuppresszió |
-
2015
- 2015-12-23 HU HUE15817385A patent/HUE043842T2/hu unknown
- 2015-12-23 WO PCT/EP2015/081157 patent/WO2016102664A1/en active Application Filing
- 2015-12-23 AU AU2015370903A patent/AU2015370903B2/en active Active
- 2015-12-23 JP JP2017552234A patent/JP6839094B2/ja active Active
- 2015-12-23 KR KR1020177020454A patent/KR102636633B1/ko active Active
- 2015-12-23 DK DK15817385.6T patent/DK3237618T3/da active
- 2015-12-23 LT LTEP15817385.6T patent/LT3237618T/lt unknown
- 2015-12-23 EP EP15817385.6A patent/EP3237618B1/en active Active
- 2015-12-23 MX MX2017008500A patent/MX2017008500A/es unknown
- 2015-12-23 SM SM20190347T patent/SMT201900347T1/it unknown
- 2015-12-23 CN CN201580071228.2A patent/CN108064292B/zh active Active
- 2015-12-23 TR TR2019/08969T patent/TR201908969T4/tr unknown
- 2015-12-23 RS RS20190744A patent/RS58862B1/sr unknown
- 2015-12-23 CA CA2971920A patent/CA2971920C/en active Active
- 2015-12-23 ES ES15817385T patent/ES2732023T3/es active Active
- 2015-12-23 EA EA201791417A patent/EA037696B1/ru unknown
- 2015-12-23 PL PL15817385T patent/PL3237618T3/pl unknown
- 2015-12-23 PT PT15817385T patent/PT3237618T/pt unknown
- 2015-12-23 SI SI201530791T patent/SI3237618T1/sl unknown
- 2015-12-23 US US15/538,964 patent/US10174321B2/en active Active
- 2015-12-23 EP EP19167349.0A patent/EP3540063A1/en active Pending
-
2017
- 2017-06-18 IL IL252990A patent/IL252990B/en unknown
- 2017-07-24 CO CONC2017/0007335A patent/CO2017007335A2/es unknown
-
2018
- 2018-04-27 HK HK18105533.3A patent/HK1246344B/zh unknown
- 2018-11-16 US US16/193,908 patent/US10767180B2/en active Active
-
2019
- 2019-05-31 HR HRP20190992TT patent/HRP20190992T1/hr unknown
- 2019-06-13 CY CY20191100616T patent/CY1121733T1/el unknown
-
2020
- 2020-07-15 US US16/930,035 patent/US11371044B2/en active Active
- 2020-10-01 JP JP2020167128A patent/JP2021000136A/ja active Pending
-
2022
- 2022-05-24 US US17/751,934 patent/US20230119344A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1246344B (zh) | Rnai誘發的亨廷頓基因抑制 | |
HK1247641A1 (zh) | 變體RNAi | |
IL250448A0 (en) | Modified double helix RNA materials | |
ZA201607100B (en) | Frequency response | |
SG11201606379UA (en) | Aptamer construct | |
IL249254B (en) | Gene expression system | |
GB201517285D0 (en) | Stabilizer arrangement | |
GB201408823D0 (en) | Demulsifiers | |
IL246956A0 (en) | targeted therapies | |
IL257500A (en) | Altered cullin1 gene | |
GB201621449D0 (en) | Frequency-domain denoising | |
IL248812A0 (en) | Very effective stabilizer | |
SG11201702844VA (en) | Photobioreactor | |
GB2547614B (en) | Stabilizer | |
SG11201700652PA (en) | Modified antimir-138 oligonucleotides | |
GB201608944D0 (en) | Gene Tharapy | |
AU5592P (en) | Lanmichigan Mandevilla boliviensis x sanderi | |
GB201410599D0 (en) | Sensitizers | |
IL230329A0 (en) | croc sponge | |
GB201403353D0 (en) | Novel oligonucleotides | |
GB201403087D0 (en) | Novel oligonucleotides | |
GB201407865D0 (en) | Nucleases |